Comparing Barinthus Biotherapeutics (BRNS) & Its Rivals

Barinthus Biotherapeutics (NASDAQ:BRNSGet Free Report) is one of 987 public companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its competitors? We will compare Barinthus Biotherapeutics to similar businesses based on the strength of its dividends, earnings, valuation, analyst recommendations, profitability, institutional ownership and risk.

Insider and Institutional Ownership

26.1% of Barinthus Biotherapeutics shares are owned by institutional investors. Comparatively, 39.8% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 6.0% of Barinthus Biotherapeutics shares are owned by insiders. Comparatively, 14.5% of shares of all “Pharmaceutical preparations” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Barinthus Biotherapeutics and its competitors gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Barinthus Biotherapeutics $44.70 million $5.34 million -1.34
Barinthus Biotherapeutics Competitors $2.14 billion $258.80 million -2.53

Barinthus Biotherapeutics’ competitors have higher revenue and earnings than Barinthus Biotherapeutics. Barinthus Biotherapeutics is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Risk and Volatility

Barinthus Biotherapeutics has a beta of -0.51, indicating that its stock price is 151% less volatile than the S&P 500. Comparatively, Barinthus Biotherapeutics’ competitors have a beta of 0.84, indicating that their average stock price is 16% less volatile than the S&P 500.

Profitability

This table compares Barinthus Biotherapeutics and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Barinthus Biotherapeutics -409.18% -34.72% -30.65%
Barinthus Biotherapeutics Competitors -1,993.05% -189.18% -30.54%

Analyst Recommendations

This is a summary of current ratings for Barinthus Biotherapeutics and its competitors, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Barinthus Biotherapeutics 0 0 2 0 3.00
Barinthus Biotherapeutics Competitors 5870 17748 42925 865 2.58

Barinthus Biotherapeutics currently has a consensus target price of $15.00, indicating a potential upside of 452.71%. As a group, “Pharmaceutical preparations” companies have a potential upside of 107.79%. Given Barinthus Biotherapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Barinthus Biotherapeutics is more favorable than its competitors.

Summary

Barinthus Biotherapeutics competitors beat Barinthus Biotherapeutics on 7 of the 13 factors compared.

About Barinthus Biotherapeutics

(Get Free Report)

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in developing novel T cell immunotherapeutics to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. It is advancing a pipeline of product candidates across a range of therapeutic areas, including VTP-300, an immunotherapeutic candidate designed as a potential component of a functional cure for chronic HBV infection; VTP-200, a non-surgical product candidate for persistent high-risk human papillomavirus (HPV); VTP-1000, an autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease; VTP-850, a second-generation immunotherapeutic candidate designed to treat recurrent prostate cancer; and VTP-1100, a preclinical cancer candidate designed to utilize the SNAP-CI platform to treat patients with HPV-related cancer. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Harwell, the United Kingdom.

Receive News & Ratings for Barinthus Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Barinthus Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.